Related Experiment Video
Updated: May 5, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Analysis of B-Scan Ultrasonography Using Neural Networks to Predict Risk of Fibrosis in Patients With Metabolic
Josefine Stansch1, Kien Vu Trung1, Valentin Blank2
1Department of Medicine II, Division of Gastroenterology, Leipzig Medical Center, Leipzig, Germany.
Objective:
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) continues to rise, underscoring the need for tools to stratify individual risk of disease progression. We evaluated whether logistic regression models augmented by deep learning-based predictions (DLPs) can improve the B-mode ultrasound-based identification of at-risk MASLD, defined as patients with increased fibrosis risk.
Methods:
We retrospectively analyzed 205 patients with a total of 636 ultrasound images. We developed a model that reproduces the LSM-based dichotomous fibrosis risk classification using clinical parameters and ultrasound image-derived deep learning pipelines. Patients were classified by same-day liver stiffness measurement (LSM) (<8 kPa: low fibrosis risk; ≥8 kPa: increased fibrosis risk). We assessed the incremental value of DLPs when added to the parameters sex, age, BMI, diabetes mellitus type 2 status and the fibrosis-4 score (FIB-4) based on accuracy, AUROC, and related statistics.
Results:
The logistic regression model combining the clinical parameters and the DLPs achieved acceptable performance with an AUROC of 0.73 and a test accuracy of 68%. The same model without DLPs showed an AUROC of 0.72 and a test accuracy of 61%. Including FIB-4 improved performance further (AUROC 0.92, accuracy 88%). Models based solely on image data demonstrated limited diagnostic performance.
Conclusion:
B-mode ultrasound provides a weak fibrosis-related signal, yielding limited diagnostic performance. Meaningful discrimination required the incorporation of clinical parameters, with FIB-4 offering the greatest improvement among the parameters assessed. Deep learning predictions added only modest incremental value. Prospective validation is needed to clarify clinical utility.

